Bipartisan bill reignites hope for lower insulin costs

Efforts to Cap Insulin Costs Intensify Amid Rising Health Concerns

Bain Brandon, a two-year-old Mississippi resident, requires insulin to manage his Type 1 diabetes. However, despite being insured, the cost of insulin is a significant burden for his parents. Last week, a one-month supply of insulin vials and a three-month supply of backup pens cost them $194, according to Marlee Brandon, his mother. The financial strain poses ample concern for their future when Bain becomes an adult and no longer qualifies for their insurance plan.

The INSULIN Act Tackles High Costs

Respite may be on the horizon as a bipartisan group of senators aims to reduce the cost of insulin through the INSULIN Act. This legislation intends to cap insulin prices at $35 per month for insured Americans. Introduced last week by Sens. Jeanne Shaheen, D-Maine, Raphael Warnock, D-Ga., Susan Collins, R-Maine, and John Kennedy, R-La., the bill also proposes a pilot program to provide affordable insulin to uninsured Americans in 10 states.

This bill follows a similar legislation passed in 2022 – the Biden-era Inflation Reduction Act, which successfully capped insulin prices at $35 per month for senior citizens on Medicare. Despite these efforts, the legislation faces numerous challenges, including cost concerns and competing congressional priorities. However, it also presents an opportunity for bipartisan agreement on health affordability, particularly when rising healthcare costs are a growing concern for voters across party lines.

The Varying Costs of Insulin

Approximately 8.1 million individuals in the U.S. rely on insulin, a vital drug for managing glucose levels in diabetes patients, according to the U.S. Centers for Disease Control and Prevention. The price of insulin, however, varies significantly. Some individuals with private insurance pay very little, while others spend hundreds of dollars each month on top of other diabetes-related expenses.

Other efforts to minimize insulin costs have seen success in recent years. Over half of U.S. states have passed legislation to cap insulin co-pays, ranging between $25 and $100 per month for patients with state-regulated insurance plans. Major insulin manufacturers Eli Lilly, Sanofi, and Novo Nordisk have also implemented measures to make insulin more affordable, though these efforts have not benefited all patients.

Previous Bills Have Fallen Short

Despite bipartisan support, this is not the first attempt at capping insulin prices. In 2022, the House of Representatives passed a bill to cap monthly insulin expenses at $35 for those with private insurance, but it did not pass the Senate. A similar effort to include a cap in the Democrats’ Inflation Reduction Act failed after Republicans opposed it for allegedly violating Senate rules.

Hope Persists Among Diabetes Patients and Advocates

Advocates remain hopeful that the latest bill will succeed. Breana Glover, a 23-year-old with Type 1 diabetes, believes a $35 cap would make insulin more accessible and help her afford other necessities. Manny Hernandez, CEO of The Diabetes Link, a national nonprofit for young adults with diabetes, also expressed optimism, particularly for the young adult population who often struggle to secure quality health insurance.